Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Mark S. Sulkowski,Kosh Agarwal,Xiaoli Ma,Tuan T. Nguyen,Eugene R. Schiff,Hie-Won L. Hann,Douglas T. Dieterich,Ronald G. Nahass,James S. Park,Sing Chan,Steven-Huy B. Han,Edward J. Gane,Michael Bennett,Katia Alves,Marc Evanchik,Ran Yan,Qi Huang,Uri Lopatin,Richard Colonno,Julie Ma

Journal of Hepatology（2022）

Cited 20|Views42
No score
Abstract
•Complete suppression of HBV replication is essential for finite treatment regimens•Vebicorvir (VBR) is an HBV core protein inhibitor developed to treat chronic HBV•VBR interferes with 2 additional steps in HBV replication and thus complements NrtIs•VBR+ETV led to a significantly deeper reduction in HBV DNA and pregenomic RNA than ETV alone•VBR+ETV was associated with favorable safety and tolerability during 24 weeks of treatment
More
Translated text
Key words
Vebicorvir,ABI-H0731,core inhibitor,chronic hepatitis B virus,entecavir,nucleos(t)ide reverse transcriptase inhibitor,treatment-naïve,phase 2
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined